Targeting Pancreatic Cancer
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has...
Progress Against Cancer
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has...
Study reports that cancer type and mortality differs among ethnic groups, suggesting a need for targeted public health efforts....
In a new study, researchers found that regular use of aspirin was associated with an almost 50 percent reduction...
Researchers urge better regulation to protect public health It’s no surprise that air pollution has been linked with lung...
The U.S. Food and Drug Administration approval provides a new option for patients who face a poor prognosis Onivyde,...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 44,000 members worldwide drive progress against cancer.
Donate Today